PKO Investment Management Joint Stock Co Buys New Holdings in IQVIA Holdings Inc. (NYSE:IQV)

PKO Investment Management Joint Stock Co acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 2,500 shares of the medical research company's stock, valued at approximately $491,000.

A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. grew its holdings in IQVIA by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock valued at $3,956,087,000 after buying an additional 105,504 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in IQVIA by 20.0% during the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after buying an additional 712,958 shares in the last quarter. Geode Capital Management LLC grew its holdings in IQVIA by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock valued at $818,315,000 after buying an additional 77,981 shares in the last quarter. Invesco Ltd. grew its holdings in IQVIA by 53.4% during the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after buying an additional 902,226 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company's stock valued at $481,380,000 after buying an additional 59,426 shares in the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their price target for the stock from $260.00 to $160.00 in a research report on Friday, April 25th. BTIG Research cut shares of IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. Wall Street Zen cut shares of IQVIA from a "buy" rating to a "hold" rating in a research report on Wednesday, March 12th. Barclays reduced their price target on shares of IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Finally, Robert W. Baird decreased their price objective on IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a report on Wednesday, May 7th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $226.32.

IQVIA Stock Down 0.6%

Shares of IQV stock traded down $0.86 during trading hours on Friday, reaching $140.16. 2,874,682 shares of the company's stock were exchanged, compared to its average volume of 1,578,625. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The stock has a market cap of $24.25 billion, a PE ratio of 18.69, a PEG ratio of 1.99 and a beta of 1.34. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12. The stock's fifty day moving average price is $150.79 and its two-hundred day moving average price is $180.93.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share for the quarter, topping analysts' consensus estimates of $2.63 by $0.07. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The business had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same quarter in the previous year, the firm earned $2.54 earnings per share. The company's revenue was up 2.5% on a year-over-year basis. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.